From: Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
ADNI-1 | ADNI-GO/2 | CN stable ADNI-1 vs. ADNI-GO/2 | |||||
---|---|---|---|---|---|---|---|
CN stable (n = 120) | CN progressors (n = 35) | p-value | CN stable (n = 163) | CN progressors (n = 8) | p-value | p-value | |
Progression to | - | 29 MCI | - | - | 7 MCI | - | |
6 AD | 1 AD | ||||||
Age at baseline (years) | 74.9 (72.0-78.5) | 77.0 (73.0-79.2) | 0.37 | 72.6 (69.4-77.1) | 83.0 (80.4-84.8) | 0.0001 | 0.0001 |
Gender (% male) | 52.5% | 57.1% | 0.49 | 50.9% | 75.0% | 0.28 | 0.89 |
Education (years) | 16.0 (14.0-18.0) | 16.0 (13.0-18.0) | 0.52 | 16.0 (15.0-18.5) | 17.0 (13.8-18.5) | 0.86 | 0.060 |
APOE ϵ4 presence | 22.5% | 31.4% | 0.39 | 29.5% | 12.5% | 0.44 | 0.22 |
ADAS-Cog | 9.33 (6.0-12.3) | 10.8 (8.6-13.3) | 0.047 | 9.0 (6.0-11) | 15.0 (13.5-16.5) | 0.0003 | 0.31 |
Memory summary score | 0.94 (0.66-1.37) | 0.71 (0.44-1.01) | 0.006 | 0.94 (0.55-1.22) | 0.22 (0.02-0.42) | 0.0004 | 0.16 |
Executive summary score | 0.66 (0.29-1.22) | 0.40 (0.03-0.77) | 0.039 | 0.82 (0.40-1.44) | 0.23 [(−0.15)-0.47] | 0.004 | 0.091 |
aHV1 | 812.0 (347.3-1244.5) | 586.8 (94.5-1322.6)] | 0.25 | 529.8 (9.0-1085.3) | −226.1 [(−419.3)-(6.7)] | 0.007 | 0.015 |
SPARE-AD | −1.44 [(−2.15)-(−0.99)] | −1.17 [(−1.74)-(−0.68)] | 0.053 | −1.32 [(−1.61)-(−1.07)] | −0.90 [(−1.04)-(−0.30)] | 0.029 | 0.019 |
HCI | 5.3 (3.3-7.5) | 6.0 (3.9-8.7) | 0.20 | 5.5 (3.5-7.7) | 7.2 (3.5-13.6) | 0.051 | 0.29 |
PC-FDG-PET | 1.38 (1.29-1.53) | 1.29 (1.23-1.43) | 0.022 | 1.45 (1.33-1.51) | 1.31 (1.20-1.36) | 0.014 | 0.54 |
Aβ1–42 (pg/ml) | 222.0 (163.5-257.0) | 210.0 (144.5-235.0) | 0.25 | 207.7 (158.3-237.3) | 147.8 (108.2-205.7) | 0.083 | 0.065 |
T-tau (pg/ml) | 60.0 (47.5-80.8) | 71.5 (54.3-95.3) | 0.13 | 56.3 (45.6-81.0) | 111.5 (93.7-123.4) | 0.032 | 0.53 |
P-tau181 (pg/ml) | 20.0 (16.0-27.5) | 22.0 (17.0-31.5) | 0.36 | 30.0 (21.9-43.1) | 35.6 (31.0-44.0) | 0.25 | <0.0001 |